Stephen Turner is an Associate Professor of Data Science and Assistant Dean for Research at the University of Virginia School of Data Science . His work bridges genomics, data science, and national security , focusing on biosecurity, synthetic biology, conservation, and bioinformatics applications in human health . Previously, he was a faculty member in the UVA School of Medicine’s Department of Public Health Sciences (2011–2019) and directed the UVA Bioinformatics Core . Ph.D., Human Genetics, Vanderbilt University M.S., Applied Statistics, Vanderbilt University B.S., Biology, James Madison University Turner’s research spans computational approaches to biosecurity, biodiversity conservation, and human health . Recent publications highlight tools like the qqman and kgp R packages, PLANES for epidemiological modeling, and biorecap for bioRxiv preprint summarization. His work integrates large-scale sequencing, genome editing, and machine learning in conservation biotechnology and public health forecasting. Scientific contributions include applications in infectious disease forecasting , forensic genomics , and maternal-fetal biology . He has mentored interdisciplinary students and collaborated on NIH-funded research , while advising biotech startups at the intersection of academia, industry, government, and policy .
Zhipeng Lu is currently an Associate Professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California (USC) School of Pharmacy. His research focuses on understanding RNA molecules and their structural complexity as a second layer of genetic instructions beyond protein encoding. He directs the Lu Lab at USC, which develops and applies novel technologies to investigate RNA structures, interactions, chemical modifications, and functions in cellular processes and animal development. Dr. Lu's research interests center on "RNA machines" in living cells, with particular emphasis on how RNA molecules fold into structures and form intermolecular interactions to execute genetic instructions. His work spans multiple dimensions of RNA biology, including RNA structure-function relationships, RNA-protein interactions, RNA modifications, and the role of RNA in human diseases such as genetic disorders and viral infections. The lab combines computational, chemical, and biological approaches to elucidate fundamental mechanisms of RNA machines, with the ultimate goal of developing new understanding and therapies targeting human diseases. Analysis of Dr. Lu's publication history reveals a strong trajectory in RNA structure and interaction mapping technologies. His work has evolved from foundational studies on RNA processing and modification to developing innovative high-throughput methods like PARIS and RISE for analyzing RNA interactomes. Recent publications focus on specific RNA systems like XIST and snoRNAs, demonstrating how his lab has moved from method development to applying these tools to solve longstanding biological questions in epigenetics and RNA therapeutics. Dr. Lu has received numerous prestigious awards recognizing his contributions to RNA research: NHGRI K99/R00 NIH Pathway to Independence Award (2017-2022) RNA Society Scaringe Award (2017) Stanford University Jump Start Award for Excellence in Research (2016-2017) Damon Runyon-Sohn Fellowship (2015-2017) His research is supported by multiple funding sources from organizations including the National Institutes of Health and other foundations. The Lu Lab is actively recruiting PhD students and postdoctoral researchers to work on several cutting-edge directions including RNA structures, interaction networks, RNA modification mechanisms, and their roles in development and disease. The lab integrates biological, chemical, and computational approaches to advance RNA biology and push forward RNA medicine. The Lu Lab at USC is a dynamic research environment focused on "RNA machines" with recent highlights including solving aspects of the orphan snoRNA problem and discovering snoRNAs that control eMet tRNA activity. The lab's vision emphasizes creative exploration of RNA biology, with researchers encouraged to pursue innovative ideas much like "wild animals running in the African savannah." Current research directions include analysis of RNA structures, interaction networks, RNA modification mechanisms, and their roles in development and disease, with applications to genetic disorders, cancers, and viral infections.
Lu Cheng is a Visiting Professor in the Department of Computer Science at the University of Helsinki, affiliated with the Vehtari Aki Professorship. He holds a Doctor of Philosophy in Natural Sciences from the University of Helsinki (2013). His research focuses on computational genomics, bioinformatics, and microbial genetics, with emphasis on DNA sequence analysis, nanopore sequencing technologies, and systems biology. He leads projects on alternative splicing in cancer and the impact of microbiota on human health. Notable contributions include the NanoBaseLib benchmark dataset and methods for RNA modification analysis. His work addresses UN Sustainable Development Goals related to good health and innovations in data science. Education: Doctor of Philosophy in Natural Sciences (2013), University of Helsinki; Doctoral degree in Natural Sciences (2013), University of Helsinki. Research Interests: Genomics, computational biology, microbial ecology, RNA sequencing technologies, and bioinformatics tool development. His projects explore bacterial population dynamics, host-pathogen interactions, and applications of machine learning in genomics. Advising: Supervises doctoral researchers including Guangzhao Cheng and Chengbo Fu. Active in grants such as the Academy of Finland Research Fellowship (2023-2025). Labs/Teams: Leads research groups focused on single-cell genomics and computational methods for biological systems.
Rachel O'Neill serves as a Board of Trustees Distinguished Professor in the Department of Molecular and Cell Biology at the University of Connecticut's College of Liberal Arts and Sciences. Her research bridges molecular genetics, cytogenetics, and computational genomics to investigate fundamental mechanisms of genome stability and evolution across diverse eukaryotic species. Her primary research interests focus on retroelement transcription, centromere function, chromosome evolution, and species-specific genomic adaptations. O'Neill's lab pioneers telomere-to-telomere (T2T) genome assembly methodologies using next-generation sequencing technologies, establishing non-traditional model organisms including marsupials, monotremes, birds, marine species, plants, and insects for comparative genome biology studies. Human Telomere-to-Telomere Consortium Primate T2T Consortium Gibbon T2T Consortium Earth Biogenomes Project Ruminant T2T Consortium Fly T2T Consortium Deep Ocean Genomes Project Antarctic Genomes Consortium Colossal Foundation UConn’s Biodiversity and Conservation Genomics program O'Neill's recent publications (2021-2025) demonstrate leadership in large-scale genomics initiatives, with significant contributions to understanding centromere biology, sex chromosome evolution, and conservation genomics. Her work spans marsupial mole genomics, ruminant chromosome evolution, and epigenetic regulation of X-chromosome inactivation, reflecting her lab's broad impact across evolutionary biology, conservation, and fundamental genome science. Her laboratory actively trains students through cohort-based programs including the RaMP Cohort and Biodiversity and Conservation Genomics Program, securing substantial collaborative funding through multi-institutional consortia. The lab maintains strong infrastructure for advanced genome assembly and epigenomic analysis, with particular expertise in challenging repetitive regions and non-model organism genomics.
Verena Siewers is a Research Professor at the Department of Biology and Biological Engineering, Chalmers University of Technology. Her work focuses on synthetic biology and metabolic engineering of yeast cell factories for producing biofuels, pharmaceuticals, nutraceuticals, and bioplastics, with particular emphasis on developing biosensor tools for pathway optimization. Key research themes: yeast-based biosensors, lipid metabolism engineering, CRISPRi/a applications, and dynamic gene regulation Notable projects include: Development of acetic acid tolerance mechanisms Optimization of fatty acid ethyl esters production Engineering phosphoketolase pathways for acetyl-CoA overproduction Her recent articles reveal trends in: CRISPR-mediated pathway engineering Stress response transcriptional profiling Heterologous plant gene expression in yeast Promoter and transcription factor engineering Funding sources: VINNOVA Novo Nordisk Foundation Carl Tryggers Stiftelse EU Horizon grants Swedish Research Council (VR) Formas
Julie K. Schwarz, MD, PhD, FASTRO is a tenured Professor of Radiation Oncology at Washington University School of Medicine, where she serves as Vice-Chair of Research and Director of the Cancer Biology Division. She also holds appointments as Professor of Cell Biology and Physiology and is affiliated with the Roy and Diana Vagelos Division of Biology & Biomedical Sciences, specifically within the Cancer Biology and Molecular Cell Biology programs. Dr. Schwarz is a key member of the Siteman Cancer Center and co-leads one of only five centers comprising the NIH's Radiation Oncology-Biology Integration Network (ROBIN). Dr. Schwarz completed her BS in Biology at Duke University (1995) followed by an MD/PhD in Cell and Molecular Biology at Washington University School of Medicine (2004) through the Medical Scientist Training Program. She completed her Internal Medicine internship (2005) and Radiation Oncology residency (2009) at Barnes-Jewish Hospital, becoming board-certified by the American Board of Radiology in Radiation Oncology (2010). Her research program focuses on translational studies of gynecologic cancers, particularly cervical cancer, with emphasis on tumor metabolism, biomarker discovery, and treatment resistance mechanisms. Dr. Schwarz's laboratory maintains one of the largest tumor repositories for cervical cancer, which includes specimens collected before and during chemoradiation treatment. Her work has demonstrated the critical role of pretreatment and post-treatment FDG-PET scanning for cervical cancer patients and has identified alterations in PI3K/Akt pathway genes associated with treatment response. Recent research directions include studying obesity's paradoxical favorable impact on cervical cancer outcomes, glucose and glutamine metabolism as targets for cancer therapy, and the role of tumor immunology in therapy resistance. Analysis of Dr. Schwarz's most recent publications reveals a strong focus on cervical cancer biology, tumor metabolism, and novel therapeutic approaches. Her work integrates clinical data with laboratory research to identify biomarkers and develop improved treatment strategies. Current research emphasizes the interface between tumor metabolism, the microenvironment, and response to therapy, with particular attention to HPV-related cancers, tumor imaging, and metabolic targets for radiosensitization. Fellow of American Society for Radiation Oncology (ASTRO) (2024) Danforth WashU Physician-Scientist Scholar Award (2024) Elected into American Society for Clinical Investigation (2022) Michael Fry Research Award for Outstanding Junior Investigator: Radiation Research Society (2012) Fellow: National Cancer Care Network (2008) RSNA Roentgen Resident/Fellow Research Award (2008) As a dedicated mentor, Dr. Schwarz has guided numerous trainees across all levels including undergraduates, graduate students, medical students, residents, fellows, and postdoctoral researchers. Her Schwarz Lab is highly collaborative and actively recruits students and researchers, with recent successes including Leahan Castillo receiving an Honorable Mention at AACR and Brett Tortelli developing significant research on the vaginal microbiome's relationship to cervical cancer treatment response. Dr. Schwarz is R01-funded and leads multiple research projects, including work on the TARGET Center which focuses on understanding the biologic effects of radiation therapy in cancer treatment. She actively participates in national organizations including the ASTRO/NCI Radiobiology Consensus Workshop, AACR Radiation Oncology Think Tank, and the ASTRO Community of Radiation Oncology Physician Scientists. Dr. Schwarz directs the Schwarz Lab, which is growing and actively recruiting postdocs, staff scientists, and graduate students. The lab employs a multidisciplinary approach combining well-annotated clinical databases, prospectively collected patient tumor banks, and state-of-the-art sequencing technologies. Current research directions include single-cell sequencing approaches to study treatment effects on tumor cells and immune cells within the tumor microenvironment, glucose and glutamine metabolism as targets for cancer therapy, and targeting myeloid-derived cells to improve anti-tumor immunity. The lab is highly collaborative and studies multiple tumor types including cervical, pancreatic, and ovarian cancers.
Professor Adele Murrell is a Professor of Epigenetics in the Department of Life Sciences at the University of Bath's Faculty of Science. She serves as Co-Director of the Centre for Therapeutic Innovation and is affiliated with both the Centre for Mathematical Biology and the Centre for Bioengineering & Biomedical Technologies (CBio). She is currently accepting doctoral students and maintains an active research program with multiple ongoing projects. Her research focuses on understanding how cells establish and maintain their specific identities through epigenetic mechanisms. Her work centers on epigenetic barriers and cell identity, genomic imprinting as a model epigenetic system, long-range epigenetic silencing in cancer, and epigenetic reprogramming during metastasis. She investigates how higher-order chromatin structure and epigenetic modifications shape the genome within the nucleus to constitute cell identity and provide memory of developmental origins. Her current work examines colon cancer and liver metastasis, focusing on changes in DNA methylation and its demethylation intermediates such as 5-hydroxymethylcytosine. Analysis of Professor Murrell's recent publications reveals a strong focus on DNA hydroxymethylation patterns in cancer progression, particularly in colorectal cancer metastasis. Her work bridges molecular epigenetics with clinical applications, exploring how epigenetic changes during metastasis could be targeted to prevent cancer spread. She has developed novel techniques for detecting epigenetic modifications and has made significant contributions to understanding allele-specific chromatin domains and genomic imprinting mechanisms. Professor Murrell leads multiple research projects including 'Two stages of genome wide 5-hydroxymethylcytosine (5hmC) reprogramming during colorectal carcinogenesis and liver metastasis' funded by the MRC until February 2024, and 'Modelling the fits and starts of how genes burst into expression' funded by The Leverhulme Trust until June 2024. She was also a Co-Investigator on the 'Multi User High-Content Confocal Microscope' project funded by the Biotechnology and Biological Sciences Research Council. Her laboratory work connects with UN Sustainable Development Goals, particularly those related to health and well-being. Her fingerprint analysis shows strong activity in Epigenetics (100%), DNA Methylation (94%), Allele research (73%), Methylation studies (69%), Genomic Imprinting (60%), CTCF research (56%), Promoter Region analysis (44%), and Differentially Methylated Regions (34%).
Apl. Prof. Dr. Felix von Stetten is an Associate Professor and Senior Scientist at the Laboratory for MEMS Applications within the Department of Microsystems Engineering (IMTEK) at the University of Freiburg. He also serves as an Executive Board Member at the Hahn-Schickard Institute of Microanalysis Systems. His work bridges academia and industry, focusing on lab-on-a-chip technologies, microfluidics, and energy harvesting for biomedical applications. Education: Studied Agricultural Sciences and Biotechnology at the Technical University of Munich, earned a PhD in Microbiology there. Post-2004, he joined IMTEK’s MEMS Applications Lab, later co-founding Hahn-Schickard’s Lab-on-a-Chip division in 2008, which became an independent institute in 2016 under his leadership. Research Interests: His work centers on miniaturized diagnostic systems (e.g., Lab-on-a-Disk platforms), energy harvesting for medical implants, and microfluidic applications. Key innovations include centrifugal microfluidic systems, smartphone-integrated diagnostic tools, and glucose fuel cell technologies. Publications: Over 1200 citations highlight contributions to microfluidic unit operations, digital PCR, and field-deployable diagnostics. Recent work emphasizes automation in pathogen detection and flexible lab-on-foil platforms. Awards: Not explicitly listed in provided texts. However, his leadership roles and impactful research suggest significant recognition in microsystems engineering. Advising/Grants: Leads major projects like BrainLinks–BrainTools and contributes to initiatives such as FRIAS and PlanOS. Manages interdisciplinary teams and collaborates with industry partners like Endress+Hauser and TwistDx. Labs/Teams: Oversees the Hahn-Schickard Institute for Microanalysis Systems and collaborates with IMTEK’s Application Development group. Active in spin-off ventures such as SpinDiag GmbH.
Matteo Dal Peraro is an Associate Professor at École polytechnique fédérale de Lausanne (EPFL) in the School of Life Sciences, where he leads the Laboratory for Biomolecular Modeling (LBM) within the Interfaculty Institute of Bioengineering (IBI). He also holds significant administrative roles as Head of IBI-SV Administration and Co-Director of IBI-STI Administration, demonstrating his leadership across both the School of Life Sciences and School of Engineering. His research bridges computational approaches with experimental validation to understand complex biological systems at multiple scales. His educational background includes a B.S. and M.S. in Physics from the University of Padua (2000), followed by a Ph.D. in Biophysics from the International School for Advanced Studies (SISSA) in Trieste (2004). He then completed postdoctoral training at the University of Pennsylvania under Professor M. L. Klein before joining EPFL as a Tenure Track Assistant Professor in late 2007. Dal Peraro's research focuses on computational biophysics and multiscale modeling of biological systems, with particular emphasis on membrane-protein interactions, nanopore sensing technologies, and structural biology. His work spans fundamental molecular mechanisms to applied educational technologies, demonstrating a commitment to both scientific discovery and knowledge dissemination. He has made significant contributions to understanding protein-membrane interactions, antibiotic resistance mechanisms, mitochondrial disorders, and viral pathogenesis through advanced computational approaches. His publication record shows a strong trend toward integrating augmented and virtual reality technologies with molecular modeling, exemplified by his development of the moleculARweb platform for chemistry and structural biology education. His research spans computational methods development, structural characterization of biomolecules, membrane biophysics, and applications to medically relevant problems including antibiotic resistance and neurodegenerative disorders. This interdisciplinary approach connects fundamental biophysical principles with practical applications in medicine and education. Dal Peraro has mentored numerous doctoral students through EPFL's PhD programs, particularly in Computational and Quantitative Biology. His leadership extends to serving on PhD program committees and directing research groups focused on computational molecular biology. He has established collaborations across multiple disciplines, facilitating integrative approaches to complex biological problems. He leads the Laboratory for Biomolecular Modeling (LBM), which develops and applies computational methods to study biological systems at multiple scales. The lab bridges molecular simulations with experimental validation, creating a synergistic approach to understanding complex biological phenomena. Dal Peraro's team has made significant contributions to membrane biophysics, protein folding, and the development of educational technologies that make structural biology accessible through augmented reality platforms.
Peng Mao is an Associate Professor in the Department of Pathology at the Renaissance School of Medicine, Stony Brook University . His research focuses on DNA damage repair mechanisms in chromatin, transcriptional regulation of repair pathways, and cancer cell adaptation to chemotherapeutic agents. Education: BS: Huazhong University of Science and Technology, China PhD: Peking University, China Postdoc: Washington State University, Pullman, WA The Mao Research Lab employs next-generation sequencing (NGS) and bioinformatics to investigate: (1) DNA repair protein dynamics in chromatin; (2) Transcription machinery's impact on DNA repair pathways; (3) Cancer-driven modulation of repair mechanisms to evade chemotherapy. His work bridges genomic instability and cancer therapy resistance . His recent publications highlight studies on UV-induced mutagenesis , cisplatin resistance , transcription-coupled repair , and chromatin remodeling complexes . These articles span genomic mapping , histone modifications , and transcription factor interactions in DNA repair contexts. Labs & Teams: Mao Research Lab, Stony Brook University
Prof. Jens Boch is a Professor at Leibniz University Hannover's Institute of Plant Genetics, specializing in plant biotechnology and genome editing. He leads the Boch group, focusing on developing crops with improved traits using TALEN and CRISPR tools. His research investigates plant pathogens like Xanthomonas , particularly their TALE effectors that manipulate host genes. Key roles include Chair of the Biology Examination Board and membership in external committees such as the Konferenz Biologischer Fachbereiche (KBF). Education & Affiliations: No explicit education details provided; affiliated with Leibniz University Hannover's Faculty of Natural Sciences. Research Interests: Genome editing applications in agriculture, bacterial pathogen strategies (e.g., Xanthomonas TALE effectors), plant defense mechanisms, and crop improvement. Recent work includes base editor developments for mitochondrial disease modeling (2025), allergen reduction in mustard (2022), and TALE-based tools for gene activation (2022). His group collaborates on projects like removing allergens and enhancing cattle heat resistance via embryo editing. Media contributions include podcasts and discussions on genome editing ethics and applications.
Professor Peter Z. Qin is a faculty member in the Department of Chemistry at the University of Southern California (USC), affiliated with the USC Dornsife College of Letters, Arts and Sciences. His research focuses on understanding nucleic acid recognition mechanisms, genome engineering, and CRISPR-Cas systems, employing advanced techniques like Site-Directed Spin Labeling (SDSL) and electron paramagnetic resonance (EPR) spectroscopy. Qin earned his Ph.D. from Columbia University (1999) and B.S. from Peking University (1991). Research interests include structural dynamics of nucleic acids, protein-nucleic acid interactions, and CRISPR-mediated DNA cleavage mechanisms. His work bridges physical chemistry and biochemistry, with applications in diagnostics, therapeutics, and gene editing. Notable contributions involve elucidating CRISPR-Cas9 and Cas12a mechanisms, DNA-unwinding checkpoints, and the role of bridge helices in target discrimination. Recent publications (2021–2025) emphasize CRISPR-Cas systems, DNA dynamics, EPR-based instrumentation, and molecular mechanisms of genome editing. His group develops tools like dual-mode EPR spectrometers and phosphorothioate-based RNA labeling techniques. The lab actively publishes in high-impact journals and collaborates on translational projects like CRISPR-engineered mouse models. Prof. Qin’s work is supported by grants and collaborations, though specific funding details are not listed. His lab maintains a dedicated website detailing ongoing research and methodologies.
Shirley Graham is a Research Fellow at the University of St Andrews School of Biology, focusing on CRISPR-Cas bacterial immune systems. Her work examines molecular mechanisms of type III CRISPR effectors, antiviral signaling pathways, and nuclease regulation. Key research areas include: Cyclic nucleotide signaling in antiviral defense Structural enzymology of CRISPR-associated nucleases CRISPR system regulation and inactivation mechanisms Bacterial-phage coevolution Recent publications characterize novel CRISPR ancillary effectors, antiviral signaling via ATP-SAM conjugation, and structural foundations of type III CRISPR complexes. Work increasingly explores therapeutic applications for antibacterial strategies and phage resistance engineering. Methodological strengths include structural biology (cryo-EM), bioinformatic discovery of defense systems, and biochemical analysis of enzyme kinetics. Research contributes to the National Center for Smart Growth and integrates computational predictions with experimental validation of immune mechanisms.
Bradley E. Aouizerat is a Professor at the College of Dentistry, New York University (NYU) , with a strong focus on oral-systemic health, genomics, and translational research. His work bridges dentistry, immunology, and chronic disease, particularly in populations affected by HIV, cancer, and health disparities. Education: BS in Microbiology/Molecular Genetics – University of California at Los Angeles PhD in Microbiology/Molecular Genetics/Immunology – University of California at Los Angeles MAS in Master of Advanced Science Research in Clinical – University of California at San Francisco His research interests span epigenetics, gene expression, pain mechanisms, microbiome, sleep, and inflammation , with a strong emphasis on biomarker discovery and minority health. He has led studies on DNA methylation in oral cancer, cytokine profiles in HIV, and the role of mitochondrial genetics in diabetes. His work often integrates machine learning and longitudinal cohort data from major studies like the Women’s Interagency HIV Study (WIHS) and Multicenter AIDS Cohort Study (MACS). His recent publications (2021–2025) reflect a broad and impactful research program, with studies in oral cancer, HIV persistence, depression in chronic disease, lymphedema, sleep disruption, and gut microbiota . These works highlight his interdisciplinary approach, combining molecular biology with clinical epidemiology and behavioral science. Key themes include epigenetic regulation of pain and opioid tolerance, neurodegenerative-like changes in cancer, and social determinants of inflammation . Scientific Awards and Recognition: Excellence in Research Mentoring Faculty Teaching Award (2013) Most Dedicated Mentor Award, PMCTR Fellowship Program (2009) Early Career Investigator Award, Bayer Healthcare International (2006) National Liver Scholar Award, American Liver Foundation (2004) Multiple early career and mentoring recognitions (2004–2006) He is an active mentor and collaborator , frequently co-authoring with junior researchers and leading interdisciplinary teams. His work has been supported by NIH-funded initiatives, including the Roadmap K12 program. He is a member of professional societies such as the American Heart Association, American Liver Foundation, and American Society for Human Genetics . He is involved in clinical and translational research teams focused on improving outcomes in cancer, HIV, and chronic pain. His lab and collaborators utilize advanced genomic and bioinformatic tools to uncover mechanisms linking biological systems with patient-reported outcomes. Future work is likely to expand on precision biomarkers, minority stress interventions, and real-time symptom detection using machine learning .
Jane A. McKeating is a Professor of Molecular Virology at the University of Oxford's Nuffield Department of Medicine. She holds the Hans Fischer Senior Fellowship at the Technical University of Munich's Institute for Advanced Study (TUM-IAS) since 2015. Her research focuses on viral infections, particularly hepatitis B (HBV) and C (HCV), exploring how hypoxia and circadian rhythms regulate viral replication and pathogenesis. She has held roles at institutions including the University of Birmingham (2005–2017) and Rockefeller University (2000–2005). Education: BSc in Biological Sciences, University of Warwick (1982) PhD in Virology, Royal Free Hospital School of Medicine, University College London (1987) Research Interests: Her work investigates how low oxygen (hypoxia) and circadian signaling pathways influence viral replication and tropism, particularly in liver and immune cells. Recent studies include SARS-CoV-2 regulation by hypoxia-inducible factors (HIFs) and circadian clock components like BMAL1. She also examines therapies targeting these pathways to combat viral infections. Publications: Her recent work spans hepatitis virus biology, antiviral screening tools, and circadian regulation of viral infections. Key themes include viral entry mechanisms, immune evasion, and drug development. Awards: 2015 Founders Award, University of Birmingham 2006 Royal Society Wolfson Merit Award 1995 Fleming Award, Society of General Microbiology Lab & Collaborations: Her research group at Oxford focuses on viral-host interactions, with collaborations on spatial transcriptomics of HBV/HDV/HIV co-infections and antiviral drug screening platforms.
